Physician profile
Jonathan J Smith
NPI 1932522547
$1,714.32
in general payments reported to CMS, 2019-2025
15 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.15 · 2022: $171 · 2023: $51.43 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Consulting Fee: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.50 |
| Consulting Fee | $475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $641.75 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $205.96 | 2025 | Tyvaso |
| Amgen INC. | $162.04 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $157.10 | 2025 | Nucala |
| Grifols USA, LLC | $135.88 | 2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.01 | 2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $75.20 | 2022-2025 | Tezspire |
| Abbvie INC. | $47.93 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $34.15 | 2025 | Winrevair |
| Insmed, INC. | $25.46 | 2025 | |
| Baxter Healthcare | $24.02 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Breas Medical, INC. | $23.87 | 2025 | Vivo 45 Ls |
| Actelion Pharmaceuticals US, INC. | $20.15 | 2025 | Opsynvi, Uptravi |
| Novartis Pharmaceuticals Corporation | $18.15 | 2025 | |
| Relievant Medsystems, INC. | $16.65 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.